A plain-language, continually updated guide from Dr. Matt Chalmers’ clinical reference on hormones and peptides.
Semax is a synthetic peptide built from a fragment of ACTH (a hormone involved in your stress response), modified with an added stabilizing sequence to help it last longer in the body. It’s a registered pharmaceutical in Russia and Ukraine, where it’s used clinically for stroke recovery and other circulatory brain disorders — its cognitive-enhancing effects come without the adrenal-stimulating action of the parent hormone.
Semax’s best-documented effect, replicated across multiple animal species and research groups, is a significant increase in BDNF (brain-derived neurotrophic factor) — a protein that drives brain cell survival, the formation of new connections between neurons, and has documented antidepressant effects. It’s also been shown to increase nerve growth factor, relevant to the health of neurons affected in conditions like Alzheimer’s, and to modulate dopamine and serotonin activity in ways connected to motivation and mood.
In Russian clinical use, Semax is used specifically in acute stroke treatment, with human research from that setting showing neuroprotective benefit in stroke, oxygen-deprivation, and traumatic brain injury models. That said, independent replication of these findings outside Russian and Ukrainian research literature has been limited in Western peer-reviewed journals — worth knowing as an honest caveat, even though the underlying BDNF research is well-established.
Because Semax has dopamine-activating effects, evening dosing can interfere with sleep — morning and midday use is generally recommended instead. There’s also a theoretical (not established) concern worth naming honestly: since BDNF promotes cell survival broadly, and chronic BDNF elevation has been implicated in some cancers, this is treated as a caution flag for chronic, long-term use rather than a confirmed risk.
Neurotrophic signaling pathways (including BDNF) are supported nutritionally by omega-3 fatty acids, B vitamins, magnesium, and zinc in the general neuroscience nutrition literature.
Semax is not FDA-approved for any indication in the United States. A related formulation is registered as a pharmaceutical for stroke and circulatory brain disorders in Russia and Ukraine. This page describes research findings only — it is not a claim about effects in humans and not an offer to treat any condition.
Semax may improve focus and cognition. It is approved in Russia as a nootropic and for certain neurological conditions, but Western medical research on it is limited.
Yes. Semax is approved and registered as a medicine in Russia.
Typical Semax nasal doses are under a milligram. Common protocols use about 0.2 to 0.6 mg per day (200 to 600 mcg), often split into one or two doses in the morning or early afternoon.
Semax is based on a fragment of the hormone ACTH and works mainly by raising BDNF, which gives it a more activating effect for focus, cognition and brain protection. Selank is based on tuftsin and works on the GABA and enkephalin systems to reduce anxiety without sedation. Both are Russian peptides of seven amino acids, used as nasal sprays, and often seen as complementary. Neither is FDA-approved.
Possibly for recovery after an ischemic stroke, based on Russian clinical data. The evidence for traumatic brain injury is weaker.
Reported side effects are generally mild, based on Russian clinical use and prescribing information.
This page draws on The Pillars Path: A Root-Cause Guide to Hormones, Peptides, and Metabolic Health by Dr. Matt Chalmers — Pillars of Wellness’ clinical reference on hormone and peptide therapy.
